Holen Sie sich die Stockscreener-App
187.03
2.57%
4.68
Handel nachbörslich:
187.03
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$182.35
Offen:
$183.815
24-Stunden-Volumen:
1.14M
Relative Volume:
1.11
Marktkapitalisierung:
$20.81B
Einnahmen:
$10.52B
Nettoeinkommen (Verlust:
$999.00M
KGV:
22.36
EPS:
8.3628
Netto-Cashflow:
$1.22B
1W Leistung:
+3.32%
1M Leistung:
+6.58%
6M Leistung:
+10.85%
1J Leistung:
+13.92%
1-Tages-Spanne:
$183.81
$187.19
1-Wochen-Bereich:
$181.37
$187.19
52-Wochen-Spanne:
$157.20
$197.55
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Vergleichen Sie DGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
187.03 | 20.29B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Strs Ohio Has $508,000 Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Esoteric Testing Research Report 2026 - GlobeNewswire Inc.
Alpha Cubed Investments LLC Grows Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest 401(k) Win Suit Faces Scrutiny at Third Circuit - USA Herald
3rd Circ. Appears Skeptical Of Quest's Early Win In 401(k) Suit - Law360
Is Quest Diagnostics Incorporated in a bullish channelSell Signal & Reliable Intraday Trade Alerts - mfd.ru
J. Safra Sarasin Holding AG Increases Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Cambiar Investors LLC Lowers Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics: A Continuing Bullish Case For A Leader Among Diagnostic Testing Brands - Seeking Alpha
A Look At Quest Diagnostics (DGX) Valuation After Recent Share Price Weakness - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Cut to Hold at Wall Street Zen - MarketBeat
3rd Circ. Preview: Citizens Bank, Quest Fight Appeals In Jan. - Law360
Stock Market Recap: Can DCWS weather a recessionPortfolio Value Report & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Rakuten Investment Management Inc. Takes $4.71 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Boston Common Asset Management LLC Has $17.92 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Named to Fortune's Most Admired Companies List for 12th Year - Intellectia AI
Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year - Chartmill
Company testing 1 in 3 U.S. adults lands Fortune 'Most Admired' spot again - Stock Titan
QRG Capital Management Inc. Sells 67,700 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Campbell & CO Investment Adviser LLC Takes $1.01 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Market Moves: Does Apogee Enterprises Inc have consistent dividend growthWeekly Market Report & Community Driven Trade Alerts - baoquankhu1.vn
Short Interest in Quest Diagnostics Incorporated (NYSE:DGX) Increases By 38.4% - MarketBeat
Klein Pavlis & Peasley Financial Inc. Purchases Shares of 5,757 Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE:DGX) Raised to Buy at Wall Street Zen - MarketBeat
How Do Investors Really Feel About Quest Diagnostics Inc? - Benzinga
TKG Advisors LLC Raises Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Nordea Investment Management AB Trims Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Aug PreEarnings: Is Quest Diagnostics Incorporated stock a value trapWatch List & AI Optimized Trade Strategies - baoquankhu1.vn
Quest Diagnostics Inc. (NYSE:DGX): A Prime Pick for Steady, Growing Dividends - Chartmill
Manning & Napier Advisors LLC Sells 11,341 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Market Rankings: What are Quest Diagnostics Incorporateds earnings expectationsJuly 2025 Market Mood & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Baird Adjusts Quest Diagnostics Price Target to $203 From $198, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics Incorporated $DGX Shares Purchased by Nisa Investment Advisors LLC - MarketBeat
Best Testosterone Replacement Therapy (TRT) 2026: Taurus Meds Consumer Analysis Examines Online TRT Access and At-Home Testosterone Treatment Options - GlobeNewswire Inc.
SG Americas Securities LLC Sells 19,597 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year? - Eastern Progress
Quest Diagnostics About To Put More Money In Your Pocket (DGX) - Nasdaq
How cyclical is Quest Diagnostics Incorporated (QDI) stock compared to rivalsGDP Growth & Free Safe Capital Growth Stock Tips - Улправда
Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs - BioSpace
Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026 - Finviz
Can Quest Diagnostics Incorporated stock sustain institutional interestJuly 2025 PostEarnings & Verified Swing Trading Watchlists - Улправда
Caldwell Trust Co Grows Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Is It Time To Reassess Quest Diagnostics (DGX) After Recent Share Price Strength? - Yahoo Finance
Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy? - Nasdaq
Data Featuring Haystack MRD from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium - Finviz
Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium - MarketScreener
Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium – Company AnnouncementFT.com - Financial Times
Assessing Quest Diagnostics (DGX) Valuation After Recent Share Price Momentum And Perceived Undervaluation - Yahoo Finance
Corewell Health, Quest Diagnostics form joint venture - Modern Healthcare
Quest Diagnostics, Corewell Health Complete Laboratory JV in Michigan - MarketScreener
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):